ACS Medi 37th National Medicinal Chemistry Symposium

COVID-19 UPDATE

With NMCS NYC 2020 due to take place end June, our team at LDO continues to plan confidently for it. We currently have NO plans to postpone or cancel.

We remain attentive to the development of the situation and follow the recommendations of the relevant health authorities. As this unprecedented situation is changing every day, we remain watchful but also focused on delivering what is an important event for the Community.

We will post updates on the website and inform all registered participants if the situation changes.

In case the symposium has to be postponed, registrations will automatically be valid for the new dates. In case of cancellation due to circumstance beyond our control - i.e. Federal State or NYC city rules and regulation - LD Organisation will offer delegates and exhibitors a voucher to access the same or a similar event scheduled at an alternative date. Neither ACS MEDI, LD Organisation, nor the Organizing Committee shall be liable for reimbursing travel costs or accommodation arrangements made by individual delegates.

We are taking into consideration the health and well being of our attendees as well as of the citizens of NYC when a final decision is made in the future.

Confirmed Speakers


Session 1: Integrating Novel Chemical Modalities in Hit-to-lead: a New Paradigm for Early Drug Discovery

Discovery and Development of Macrocyclic Peptides for the Treatment of Complement-Mediated Disorders
Dr Susan ASHWELLDr Susan ASHWELL
(RA PHARMA, Cambridge, United States)

Read more
Impact of Structure Based Drug Design in GPCR Lead Optimisation Strategies
Dr Miles CONGREVEDr Miles CONGREVE
(SOSEI HEPTARES, Welwyn Garden City, United Kingdom)

Read more
Translating RNA Sequence into Lead Small Molecule Medicines
Prof. Matthew DISNEYProf. Matthew DISNEY
(SCRIPPS RESEARCH INSTITUTE, Jupiter, United States)

Read more
Structural Approach to Identify Lead Scaffolds for Protein-Protein Interaction Targets
Prof. Kyle HADDENProf. Kyle HADDEN
(UNIVERSITY OF CONNECTICUT, Storrs, United States)

Read more
Protein Degradation beyond Oncology
Dr Nello MAINOLFIDr Nello MAINOLFI
(KYMERA THERAPEUTICS, Cambridge, United States)

Read more
Integrating DNA-Encoded Library Technologies in Lead Discovery
Dr Lisa MARCAURELLEDr Lisa MARCAURELLE
(GSK, Cambridge, United States)

Read more

Session 2: New Directions in Targeting DNA Damage Repair (DDR)

Discovery and Optimization of Novel PARG Inhibitors
Dr Hilary BECKDr Hilary BECK
(IDEAYA BIOSCIENCES, SOUTH SAN FRANCISCO, United States)

Read more
Discovery of Potent and Selective DNA-PK Inhibitors via Structure-Guided Virtual Screening Strategies
Dr Charlene FALLANDr Charlene FALLAN
(ASTRAZENECA, Cambridge, United Kingdom)

Read more
M3541 and M4076: Discovery and Optimization of Potent and Selective ATM Kinase Inhibitors with Strong Anti-tumor Efficacy in Combination Therapies
Dr Thomas FUCHSSDr Thomas FUCHSS
(MERCK KGAA - MERCK BIOPHARMA, Darmstadt, Germany)

Read more
Discovery of DNA Polymerase theta (Polθ) Inhibitors: HTS to in vitro Probes
Dr Robert HEALDDr Robert HEALD
(ARTIOS PHARMA LTD, Cambridge, United Kingdom)

Read more
Damage Incorporated: Discovery of ATR Inhibitor BAY 1895344 with Favorable PK Properties and Promising Anti-Tumor Efficacy in Monotherapy and Combination in Preclinical Tumor Models
Dr Ulrich LÜCKINGDr Ulrich LÜCKING
(BAYER AG, Berlin, Germany)

Read more
The Modification of Pyrazolopyrimidinones and their Effect on WEE1 Inhibition and the DNA Damage Response
Prof. Phil REIGANProf. Phil REIGAN
(UNIVERSITY OF COLORADO, Aurora, United States)

Read more

Session 3: Hot Targets from NYC Academic and Biotech Scene

Designing and Combining Cancer's Off Switches
Dr Karen AKINSANYADr Karen AKINSANYA
(SCHRODINGER, New York City, United States)

Read more
Rational Design of Inhibitors of Protein-Protein Interactions
Prof. Paramjit ARORAProf. Paramjit ARORA
(NYU, New York, United States)

Read more
Next Generation Drug Discovery
Dr Steve COLLETTIDr Steve COLLETTI
(LODO THERAPEUTICS, New York, United States)

Read more
Optimization of Mycobacterium Tuberculosis (Mtb) Selective Inhibitors of Lipoamide Dehydrogenase (Lpd)
Dr John GINNDr John GINN
(TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, New York, United States)

Read more
Therapeutic Potential of the Gut-Brain Axis
Dr Ann WEBERDr Ann WEBER
(KALLYOPE, New York, United States)

Read more

Session 4: Targeting Autophagy for Cancer, Neurodegeneration, or Autoimmune Disease

The Development of Substrate Competitive and Allosteric Inhibitors of Cysteine Protease ATG4B to Prevent Autophagic Flux
Dr Jason CROSSDr Jason CROSS
(MD ANDERSON CANCER CENTER, Houston, United States)

Read more
Title of talk to be confirmed
Dr Peter FULLERDr Peter FULLER
(MERCK & CO. INC., Boston, United States)
Chemical Activation of Chaperone-Mediated Autophagy for Protection against Neurodegeneration
Prof. Evripidis GAVATHIOTISProf. Evripidis GAVATHIOTIS
(ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States)

Read more
Activating PTEN-Induced Kinase 1 (PINK1) for Parkinson’s Disease
Dr Nicholas HERTZDr Nicholas HERTZ
(MITOKININ INC, San Francisco, United States)

Read more
Unraveling Autophagy in Cancer Using Chemical Genetics
Prof. Jeff MACKEIGANProf. Jeff MACKEIGAN
(MICHIGAN STATE UNIVERSITY, East Lansing, United States)

Read more
Discovery of Highly Potent and Selective Vacuolar Protein Sorting 34 (Vps34) Inhibitors
Dr Jenny VIKLUNDDr Jenny VIKLUND
(SPRINT BIOSCIENCE AB, Huddinge, Sweden)

Read more

Session 5: Next Generation Therapies Shaped by Clinical Data

3 Generations of RAF Inhibitors – Learnings and Improvements Based on Clinical Data
Dr Robert AVERSADr Robert AVERSA
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States)

Read more
Discovery of Oral CGRP Receptor Antagonists for the Treatment of Migraine: Learning from (Clinical) Experience
Dr Christopher BURGEYDr Christopher BURGEY
(MERCK & CO., INC., West Point, United States)

Read more
LPA1 Receptor Antagonists for the Treatment of IPF
Dr Peter CHENGDr Peter CHENG
(BRISTOL-MYERS SQUIBB R & D, Hopewell, United States)

Read more
Leveraging the Human PK of PF-06882961, an Oral Small Molecule GLP-1R Agonists, in the Discovery of a 2nd Generation Candidate
Dr David GRIFFITHDr David GRIFFITH
(PFIZER INC., Cambridge, United States)

Read more
Discovery of Risdiplam, a Selective SMN2 Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy
Dr Hasane RATNIDr Hasane RATNI
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

Read more
Evolution of Clinical PI3K Inhibitors at Genentech
Dr Steve STABENDr Steve STABEN
(GENENTECH, South San Francisco, United States)

Read more

Session 6: Lessons from Drug Hunters across Academia, NPOs and the Pharmaceutical Industry

Discovery of Novel Drug Regimens for the Treatment of Tuberculosis
Dr Christopher B. COOPERDr Christopher B. COOPER
(TB ALLIANCE, GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, New York, United States)

Read more
Discovery of Upadacitinib: a Tricyclic Janus Kinase 1 (JAK1) Inhibitor
Dr Kristine E. FRANKDr Kristine E. FRANK
(ABBVIE, North Chicago, United States)

Read more
DSM265, a Dihydroorotate Dehydrogenase Inhibitor for the Treatment of Malaria
Prof. Meg PHILLIPSProf. Meg PHILLIPS
(UNIVERSITY OF TEXAS SOUTHWESTERN MED CENTER, Dallas, United States)

Read more
Discovery of the Selective Allosteric TYK2 Inhibitor BMS-986165 for the Treatment of Autoimmune Diseases
Dr Steve WROBLESKIDr Steve WROBLESKI
(BRISTOL-MYERS SQUIBB, Princeton, United States)

Read more
Delivering Innovative Medicines: Small Changes can have a Large Effect
Dr Wendy YOUNGDr Wendy YOUNG
(GENENTECH, South San Francisco, United States)

Read more

Award Session

2020 IUPAC-Richter Prize Lecture
How I Spent my Summer Vacation: Insights from a 30-year Career in Drug Discovery (and Molecules that have Broken my Heart)
Dr John E. MACORDr John E. MACOR
(SANOFI, Waltham, United States)

Read more
2020 Division of Medicinal Chemistry Award Lecture
Title of Talk to be confirmed
Prof. Shaomeng WANGProf. Shaomeng WANG
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

Organized by

Gold Sponsors

Silver Sponsors

Bronze Sponsors

Copyright 2020 LD Organisation srl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys